Clinical evaluation of Udarda Prashamana Mahakashaya In The Management Of Udarda (Urticaria )

CLINICAL EVALUATION OF UDARDA PRASHAMANA MAHAKASHAYA IN THE MANAGEMENT OF UDARDA W.S.R. TO URTICARIA: A RANDOMIZED CONTROLLED TRIAL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/033237

Enrollment

Registered

2021-04-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: Udarda Prashamana Mahakashaya: 40 ml twice in a day orally, before meal for 28 days Control Intervention1: Tab. cetirizine: 1 tablet (10 mg) once in a day orally, after dinner for 28 da

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient willing to give consent for clinical trial. 2.Patient having any clinical signs and symptoms of Udarad (Urticaria). 3.Patient having chronicity less then 5 year duration.

Exclusion criteria

Exclusion criteria: 1.Patients with long term history of steroid and cytotoxic treatment. 2.Patients having concomitant illness like uncontrolled Hypertension,Diabetes Mellitus,Malignancy etc. 3.Pregnant and lactating women. 4.Angioedema of the lips, tongue or larynx. 5.Patients having other associated skin disease like eczema, secondary bacterial infection

Design outcomes

Primary

Measure	Time frame
Changes in sign and symptoms of Udarda.Timepoint: 28 Days	—

Secondary

Measure	Time frame
Changes in Urticaria Activity Score.Timepoint: 28 Days	—

Countries

India

Contacts

Public ContactSumit

National Institute of Ayurveda

harishbhakuni78@gmail.com7891233108

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026